Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese VolunteersGlobeNewsWire • 09/28/21
Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021GlobeNewsWire • 09/27/21
Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021GlobeNewsWire • 09/07/21
Are Options Traders Betting on a Big Move in Altimmune (ALT) Stock?Zacks Investment Research • 08/27/21
Altimmune, Inc. (ALT) CEO Vipin Garg on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/11/21
Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 08/10/21
Altimmune to Announce Second Quarter 2021 Financial Results on August 11, 2021GlobeNewsWire • 08/04/21
Will Altimmune, Inc. (ALT) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 08/03/21
Altimmune, Inc. (ALT) Soars 16.5%: Is Further Upside Left in the Stock?Zacks Investment Research • 06/17/21
Altimmune's ALT-801 Achieves 5.4% Weight Loss Surpassing Pre-Established Target Of 2%Benzinga • 06/16/21